Company profile: CancerVax
1.1 - Company Overview
Company description
- Provider of novel biological products for cancer treatment and control, focused on specific active immunotherapy. Offerings include a Universal Cancer Vaccine (UCV) platform that forces cancer cells to express a unique protein marker for precise immune targeting, a Universal CAR-T (UCAR-T) platform that reprograms natural T-cells inside the body to destroy targeted cancer cells, and an Ewing sarcoma immunotherapy.
Products and services
- Ewing Sarcoma Immunotherapy: Single-disease specific immunotherapy targeting Ewing sarcoma in bone and soft tissue, primarily affecting children and young adults, enabling focused tumor targeting with disease-specific precision
- Universal Cancer Vaccine (UCV) Platform: Marker-driven platform forces cancer cells to express a unique protein marker, enabling the immune system to precisely identify, target, and destroy malignant cells
- Universal CAR-T Cell Platform (UCAR-T): Customizable platform reprograms natural immune T-cells inside the body to seek and destroy targeted cancer cells with precise, target-directed activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CancerVax
Genflow Biosciences
HQ: United States
Website
- Description: Provider of synthetic biology-based gene therapies to delay or stop aging in humans and dogs, focused on the development and promotion of creative treatments that target aging to extend life expectancy in both humans and canines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genflow Biosciences company profile →
Vertellus
HQ: United States
Website
- Description: Provider of specialty chemical ingredients for pharmaceuticals, personal care, nutrition, and agriculture, with emphasis on green chemistries. #1 global producer of pyridine, picolines, specialty pyridine derivatives, and DEET. Products include small-molecule APIs; biocompatible polyurethane adhesives/sealants for medical devices; nutraceuticals (Vitamin B3, Zinc, Potassium Chloride); sugar- and amino acid-based surfactants; and silicone-free pigment dispersants for mineral UV filters.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vertellus company profile →
Lightcast
HQ: United Kingdom
Website
- Description: Provider of a droplet-based microfluidics and oEWOD platform for parallel and sequential single-cell assays, live-cell recovery for downstream applications, and multi-step workflows that streamline lead identification and optimization in drug discovery, supporting basic and translational research on cell-to-cell communication, immune function, and the impact of CRISPR edits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lightcast company profile →
UBC
HQ: United States
Website
- Description: Provider of pharmaceutical support services for life science companies, including evidence development, safety and risk management, patient access, technology solutions, and clinical services. UBC leverages real-world data, technology, and analytics to enhance late-stage research, demonstrate safety, improve access and adherence, and speed therapy initiation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full UBC company profile →
Arcus Medica
HQ: United States
Website
- Description: Provider of medical and scientific communications consulting services with full-service capabilities and expertise in oncology, hematology, transplant, and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcus Medica company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CancerVax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CancerVax
2.2 - Growth funds investing in similar companies to CancerVax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CancerVax
4.2 - Public trading comparable groups for CancerVax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →